X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (29) 29
index medicus (26) 26
animals (17) 17
pharmacology & pharmacy (9) 9
von willebrand factor (9) 9
drug candidate alx-0081 (8) 8
medicine, research & experimental (8) 8
cancer (7) 7
hematology (7) 7
platelet aggregation inhibitors - therapeutic use (7) 7
von-willebrand-factor (7) 7
proteins (6) 6
thrombosis (6) 6
biology (5) 5
blood platelets - drug effects (5) 5
cardiovascular-disease (5) 5
clinical trials as topic (5) 5
female (5) 5
peripheral vascular disease (5) 5
platelet aggregation inhibitors - pharmacology (5) 5
von willebrand factor - immunology (5) 5
von willebrand factor - metabolism (5) 5
adamts13 protein (4) 4
binding (4) 4
biotechnology (4) 4
blood platelets (4) 4
cardiac & cardiovascular systems (4) 4
cardiology (4) 4
disease (4) 4
drug design (4) 4
drug discovery (4) 4
drug therapy (4) 4
efficacy (4) 4
fibrinolytic agents - pharmacology (4) 4
fibrinolytic agents - therapeutic use (4) 4
health aspects (4) 4
immunoglobulin fragments - therapeutic use (4) 4
male (4) 4
mice (4) 4
middle aged (4) 4
monoclonal-antibodies (4) 4
multidisciplinary sciences (4) 4
platelet aggregation - drug effects (4) 4
risk (4) 4
single-domain antibodies - therapeutic use (4) 4
stroke (4) 4
therapeutics (4) 4
thrombotic thrombocytopenic purpura (4) 4
treatment outcome (4) 4
von willebrand factor - antagonists & inhibitors (4) 4
acute coronary syndromes (3) 3
aged (3) 3
antibody therapeutics (3) 3
arterial thrombosis (3) 3
atherosclerosis (3) 3
biomedical engineering (3) 3
biomedicine general (3) 3
bioscience (3) 3
blood platelets - metabolism (3) 3
calcium (3) 3
cancer-therapy (3) 3
caplacizumab (3) 3
cardiovascular disease (3) 3
cell (3) 3
circulatory and respiratory physiology (3) 3
coronary artery disease - blood (3) 3
cycle (3) 3
double-blind (3) 3
drugs (3) 3
dysfunction (3) 3
fragments (3) 3
health risk assessment (3) 3
heart attacks (3) 3
hemic and lymphatic diseases (3) 3
human genetics (3) 3
landes (3) 3
libraries (3) 3
medicine (3) 3
medicine & public health (3) 3
medicine/public health, general (3) 3
myocardial-infarction (3) 3
nanobody (3) 3
organogenesis (3) 3
peptide library (3) 3
percutaneous coronary intervention (3) 3
platelet aggregation inhibitors - administration & dosage (3) 3
platelet aggregation inhibitors - adverse effects (3) 3
research (3) 3
research article (3) 3
review (3) 3
safety (3) 3
science (3) 3
thrombocytopenic purpura (3) 3
tumors (3) 3
von willebrand disease (3) 3
abridged index medicus (2) 2
active metabolite (2) 2
acute myocardial infarction (2) 2
acute myocardial-infarction (2) 2
adamts13 (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Thrombosis and Haemostasis, ISSN 0340-6245, 07/2011, Volume 106, Issue 1, pp. 165 - 171
Journal Article
Journal of Cardiovascular Translational Research, ISSN 1937-5387, 6/2013, Volume 6, Issue 3, pp. 355 - 363
This manuscript reviews the studies performed with ALX-0081 (INN: caplacizumab), a Nanobody targeting von Willebrand factor, in the context of current... 
Human Genetics | Antiplatelet inhibition | Adjunctive pharmacotherapy | Percutaneous coronary intervention | Medicine/Public Health, general | Biomedicine general | ALX-0081 Nanobody | Biomedical Engineering | Thrombotic thrombocytopenic purpura | Medicine & Public Health | von Willebrand factor | Antithrombotic | Caplacizumab | Cardiology | Acute coronary syndrome | MEDICINE, RESEARCH & EXPERIMENTAL | STABLE ANGINA | CARDIAC & CARDIOVASCULAR SYSTEMS | MANAGEMENT | RESIDUAL PLATELET REACTIVITY | THROMBOSIS | SYNDROMES DIAGNOSIS | CLOPIDOGREL | INHIBITION | GLYCOPROTEIN | ELEVATION MYOCARDIAL-INFARCTION | Single-Domain Antibodies - therapeutic use | Blood Platelets - immunology | Single-Domain Antibodies - adverse effects | von Willebrand Factor - immunology | Humans | Treatment Outcome | Coronary Artery Disease - blood | Coronary Thrombosis - immunology | Fibrinolytic Agents - adverse effects | Animals | Coronary Artery Disease - therapy | von Willebrand Factor - antagonists & inhibitors | Blood Platelets - metabolism | Fibrinolytic Agents - therapeutic use | Coronary Thrombosis - prevention & control | Coronary Artery Disease - immunology | Hemorrhage - chemically induced | Blood Platelets - drug effects | Platelet Aggregation Inhibitors - therapeutic use | Coronary Thrombosis - blood | Percutaneous Coronary Intervention - adverse effects | Platelet Aggregation Inhibitors - adverse effects | von Willebrand Factor - metabolism | Health aspects | Coronary heart disease | Von Willebrand factor
Journal Article
Journal of thrombosis and haemostasis, ISSN 1538-7933, 2013, Volume 11, Issue 5, pp. 845 - 854
Journal Article
Current Vascular Pharmacology, ISSN 1570-1611, 2013, Volume 11, Issue 4, pp. 448 - 456
Journal Article
Blood, ISSN 0006-4971, 11/2012, Volume 120, Issue 20, pp. 4134 - 4142
Journal Article
Journal Article
DRUGS OF THE FUTURE, ISSN 0377-8282, 10/2016, Volume 41, Issue 10, pp. 589 - 594
Thrombotic thrombocytopenic purpura (TTP) is characterized by the presence of multiple platelet-rich microthrombi. Patients with acquired TTP generate... 
Anti-von Willebrand factor | Coagulation disorders | EFFICACY | SAFETY | DRUG CANDIDATE ALX-0081 | PURPURA | FACTOR-CLEAVING PROTEASE | MEMBER | FAMILY | Antiplatelet therapy | TTP | Thrombotic thrombocytopenic purpura | PHARMACOLOGY & PHARMACY | Caplacizumab
Journal Article
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, ISSN 1538-7933, 05/2013, Volume 11, Issue 5, pp. 845 - 854
Background: High von Willebrand factor (VWF) levels are an established risk factor for arterial thrombosis, including coronary heart disease and ischemic... 
cardiovascular disease | ADULT PATIENTS | HEMOPHILIA PATIENTS | NONFATAL CARDIOVASCULAR-DISEASE | DRUG CANDIDATE ALX-0081 | ATHEROSCLEROSIS | RISK | ISCHEMIC-HEART-DISEASE | FACTOR PLASMA-LEVELS | STROKE | von Willebrand factor | von Willebrand disease | VONWILLEBRAND DISEASE | acute myocardial infarction | ischemic stroke
Journal Article
Journal of Cardiovascular Translational Research, ISSN 1937-5387, 6/2013, Volume 6, Issue 3, pp. 364 - 370
ALX-0081 is a novel nano-antibody inhibiting von Willebrand factor (vWF). We evaluated whether direct inhibition of vWF by ALX-0081 improves endothelial... 
Human Genetics | Biomedical Engineering | Medicine & Public Health | von Willebrand factor | PCI | Nano-antibody | Endothelial function | Cardiology | Medicine/Public Health, general | Coronary artery disease | Biomedicine general | MEDICINE, RESEARCH & EXPERIMENTAL | VASOMOTION | CARDIAC & CARDIOVASCULAR SYSTEMS | CYCLIC FLOW VARIATIONS | CORONARY ATHEROSCLEROSIS | THROMBOXANE | INFLAMMATION | DISEASE | PERIPHERAL ARTERIAL TONOMETRY | DYSFUNCTION | BLOOD | Prospective Studies | von Willebrand Factor - immunology | Humans | Middle Aged | Molecular Sequence Data | Endothelium, Vascular - drug effects | Male | Coronary Artery Disease - blood | Flow Cytometry | Cell-Derived Microparticles - drug effects | Time Factors | von Willebrand Factor - antagonists & inhibitors | Female | Cell-Derived Microparticles - metabolism | Angina, Stable - immunology | Platelet Aggregation Inhibitors - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | von Willebrand Factor - metabolism | Angina, Stable - therapy | Manometry | Single-Domain Antibodies - therapeutic use | Double-Blind Method | Single-Domain Antibodies - adverse effects | Endothelial Cells - metabolism | Endothelium, Vascular - physiopathology | Treatment Outcome | Biomarkers - blood | Angina, Stable - blood | Coronary Artery Disease - therapy | Belgium | Endothelium, Vascular - metabolism | Aged | Hemodynamics - drug effects | Coronary Artery Disease - immunology | Percutaneous Coronary Intervention - adverse effects | Endothelial Cells - drug effects | Care and treatment | Angina pectoris | Von Willebrand factor | Endothelium
Journal Article
Journal Article
PLoS ONE, ISSN 1932-6203, 08/2015, Volume 10, Issue 8, p. e0135278
Journal Article